Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid

Isoniazid is a key drug used in the treatment of tuberculosis. Isoniazid is a pro-drug, which, after activation by the katG-encoded catalase peroxidase, reacts nonenzymatically with NAD+ and NADP+ to generate several isonicotinoyl adducts of these pyridine nucleotides. One of these, the acyclic 4S isomer of isoniazid-NAD, targets the inhA-encoded enoyl-ACP reductase, an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Here we show that the acyclic 4R isomer of isoniazid-NADP inhibits the M. tuberculosis dihydrofolate reductase (DHFR), an enzyme essential for nucleic acid synthesis. This biologically relevant form of the isoniazid adduct is a subnanomolar bisubstrate inhibitor of M. tuberculosis DHFR. Expression of M. tuberculosis DHFR in Mycobacterium smegmatis mc2155 protects cells against growth inhibition by isoniazid by sequestering the drug. Thus, M. tuberculosis DHFR is the first new target for isoniazid identified in the last decade.

[1]  G. W. Raiziss,et al.  Chemotherapy of Experimental Tuberculosis. , 1941 .

[2]  G. Middlebrook.  Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. , 1952, American review of tuberculosis.

[3]  W. A. Lott,et al.  Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. , 1952, American review of tuberculosis.

[4]  M. Uschold,et al.  Methods and applications , 1953 .

[5]  F. Harold,et al.  Selective Inhibition of Nucleic Acid Synthesis in Mycobacterium tuberculosis by Isoniazid , 1963, Nature.

[6]  J. Youatt.  A review of the action of isoniazid. , 1969, The American review of respiratory disease.

[7]  J. Morrison,et al.  Kinetic mechanism of the reaction catalyzed by dihydrofolate reductase from Escherichia coli. , 1982, Biochemistry.

[8]  Christopher J. L. Murray,et al.  Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.

[9]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[10]  Axel T. Brunger,et al.  Assessment of Phase Accuracy by Cross Validation: the Free R Value. Methods and Applications , 1993 .

[11]  A. Brünger.  Assessment of phase accuracy by cross validation: the free R value. Methods and applications. , 1993, Acta crystallographica. Section D, Biological crystallography.

[12]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[13]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[14]  S. Cole,et al.  Mechanisms of drug resistance in Mycobacterium tuberculosis. , 1994, Immunobiology.

[15]  J C Sacchettini,et al.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.

[16]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[17]  J. Kraut,et al.  Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence. , 1997, Biochemistry.

[18]  T. Weisbrod,et al.  Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Sacchettini,et al.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.

[20]  G. Miller,et al.  Stretching exercises--flexibility in dihydrofolate reductase catalysis. , 1998, Chemistry & biology.

[21]  R. Slayden,et al.  Mycolic acids: structure, biosynthesis and physiological functions. , 1998, Progress in lipid research.

[22]  W. Jacobs,et al.  Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. , 1998, The Journal of infectious diseases.

[23]  R. Reynolds,et al.  Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. , 1998, The Journal of antimicrobial chemotherapy.

[24]  P. Brown,et al.  Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Wilming,et al.  Spontaneous Formation of the Bioactive Form of the Tuberculosis Drug Isoniazid. , 1999, Angewandte Chemie.

[26]  James C. Sacchettini,et al.  Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.

[27]  W G Hol,et al.  Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. , 2000, Journal of molecular biology.

[28]  M. Nguyen,et al.  A Fast and Efficient Metal‐Mediated Oxidation of Isoniazid and Identification of Isoniazid–NAD(H) Adducts , 2001, Chembiochem : a European journal of chemical biology.

[29]  V. Cody,et al.  Analysis of three crystal structure determinations of a 5-methyl-6-N-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase. , 2003, Acta crystallographica. Section D, Biological crystallography.

[30]  M. Lennon,et al.  Signature Gene Expression Profiles Discriminate between Isoniazid-, Thiolactomycin-, and Triclosan-Treated Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[31]  D. Bumann,et al.  The RD1 proteins of Mycobacterium tuberculosis: expression in Mycobacterium smegmatis and biochemical characterization. , 2003, Microbes and infection.

[32]  Peter J. Tonge,et al.  The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Myers,et al.  The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism , 2004, Journal of Biological Chemistry.

[34]  G. Labesse,et al.  In Vitro Inhibition of the Mycobacterium tuberculosis β-Ketoacyl-Acyl Carrier Protein Reductase MabA by Isoniazid , 2004, Antimicrobial Agents and Chemotherapy.

[35]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[36]  G. Besra,et al.  The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. , 2004, Tuberculosis.

[37]  Peter E Wright,et al.  Structure, dynamics, and catalytic function of dihydrofolate reductase. , 2004, Annual review of biophysics and biomolecular structure.

[38]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[39]  G. Besra,et al.  Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.

[40]  Yongyuth Yuthavong,et al.  Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Jie J. Zheng,et al.  The structural biology of type II fatty acid biosynthesis. , 2005, Annual review of biochemistry.

[42]  Scott J Geromanos,et al.  Quantitative proteomic analysis of drug-induced changes in mycobacteria. , 2006, Journal of proteome research.